Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of intensive treatment versus standard treatment of compound danshen dripping pills in refractory angina patients unsuitable for revascularization: a multicenter, randomized, double-blind, parallel controlled clinical trial

Trial Profile

Efficacy and safety of intensive treatment versus standard treatment of compound danshen dripping pills in refractory angina patients unsuitable for revascularization: a multicenter, randomized, double-blind, parallel controlled clinical trial

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T 89 (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Oct 2018 Planned number of patients changed from 168 to 10.
    • 14 Oct 2018 Planned End Date changed from 30 Jun 2019 to 31 Dec 2020.
    • 06 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top